The company plans to cancel 4,763,348 shares of treasury stock (6.34% of the total outstanding shares) on May 12, 2026. After cancellation, the total number of outstanding shares will be 70,401,547 shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4530","jir_company_name":"Hisamitsu Pharmaceutical Co., Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-03-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4530-20260313-02.pdf","jir_short_summary":"The company plans to cancel 4,763,348 shares of treasury stock (6.34% of the total outstanding shares) on May 12, 2026. After cancellation, the total number of outstanding shares will be 70,401,547 shares.","jir_summary":"### Overview of Capital Policy\nAt the Board of Directors meeting held on March 13, 2026, Hisamitsu Pharmaceutical Co., Inc. resolved to cancel 4,763,348 shares of treasury stock held by the company in accordance with Article 178 of the Companies Act. This amount corresponds to 6.34% of the total outstanding shares before cancellation. The scheduled cancellation date is May 12, 2026, after which the total number of outstanding shares will be 70,401,547 shares. The cancellation is conditional upon approval of agenda items including share consolidation at the extraordinary general meeting of shareholders scheduled for April 17, 2026.\n\n### Impact on Shareholders and Future Outlook\nThis treasury stock cancellation will reduce the number of outstanding shares, which is expected to enhance the value per share. The cancellation covers all treasury shares held and aims to improve capital efficiency. It is part of procedures related to share consolidation and the abolition of the designation of unit shares. The cancellation will be implemented following approval at the extraordinary general shareholders meeting. Investors should pay close attention to the resolutions at upcoming shareholders meetings.","jir_financial_highlights":"Number of shares to be cancelled: 4,763,348 shares (Ratio to total outstanding shares: 6.34%)\nScheduled cancellation date: 2026-05-12 (Unknown)\nTotal outstanding shares after cancellation: 70,401,547 shares (Unknown)","jir_category":"","jir_hashtags":"#HisamitsuPharmaceutical, #TreasuryStockCancellation, #CapitalPolicy, #JapaneseStocks","jir_key_figures":"Number of treasury shares to be cancelled: 4,763,348 shares (6.34% of total outstanding shares)\nScheduled cancellation date: 2026-05-12\nTotal outstanding shares after cancellation: 70,401,547 shares","jir_meta_title":"Hisamitsu Pharmaceutical to Cancel 4,763,348 Shares of Treasury Stock (6.34%) on May 12, 2026","jir_meta_description":"Hisamitsu Pharmaceutical Co., Inc. plans to cancel 4,763,348 shares of treasury stock (6.34% of total outstanding shares) on May 12, 2026. This is a capital efficiency improvement measure conditional on approval at an extraordinary shareholders meeting.","jir_og_title":"Hisamitsu Pharmaceutical to Cancel 6.34% of Treasury Stock","jir_og_description":"Hisamitsu Pharmaceutical plans to cancel 4,763,348 shares of treasury stock on May 12, 2026, subject to shareholders meeting approval.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8125,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-34655","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n